Good
Mostly Aligned
Patient Risk:
Low
Summary
Most safety/efficacy general statements (sedation/somnolence, dizziness, neuropathic pain, fibromyalgia, seizure adjunctive use, mechanism of action) are consistent with the provided label excerpts. However, multiple claims about benzodiazepine mechanism are not addressed in the supplied label text, and therefore cannot be supported. Also, some indication wording is broadly correct but includes terms ('nerve pain') that are not explicitly used as such in the label excerpts.
Category Scores
Accurate Statements
Lyrica (pregabalin) is an anticonvulsant.
Label indicates LYRICA as adjunctive therapy for partial-onset seizures (Section 1 INDICATIONS AND USAGE; Section 14.3).
Lyrica (pregabalin) is a pain medication.
Label indicates LYRICA for management of neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury-related neuropathic pain) and for fibromyalgia pain (Section 1 INDICATIONS AND USAGE).
Lyrica (pregabalin) affects how nerve signals travel in the body.
Mechanism of action described as binding to alpha2-delta site in CNS tissues (Section 12.1).
Lyrica (pregabalin) is commonly prescribed for nerve pain (neuropathic pain).
Indications include management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and neuropathic pain associated with spinal cord injury (Section 1 INDICATIONS AND USAGE).
Lyrica (pregabalin) is commonly prescribed for fibromyalgia.
Indication for management of fibromyalgia (Section 1 INDICATIONS AND USAGE).
Lyrica (pregabalin) is commonly prescribed for certain types of seizures.
Indication for adjunctive therapy for partial-onset seizures in patients 1 month of age and older (Section 1 INDICATIONS AND USAGE; Section 14.3).
Lyrica can cause sedation.
Label: dizziness and somnolence are possible adverse effects (Section 5.5).
Lyrica can cause dizziness.
Label: LYRICA may cause dizziness and somnolence (Section 5.5).
Unsupported Statements
Lyrica (pregabalin) is not a benzodiazepine.
Provided label excerpts do not mention benzodiazepines or explicitly state that pregabalin is not a benzodiazepine.
Lyrica does not act as a benzodiazepine.
Provided label excerpts do not discuss benzodiazepine mechanisms or explicitly compare pregabalin to benzodiazepines.
Lyrica does not work through the same benzodiazepine mechanisms.
Provided label excerpts describe pregabalin mechanism (alpha2-delta binding) but do not address benzodiazepine mechanisms or make comparative statements.
Lyrica (pregabalin) is commonly prescribed for nerve pain (neuropathic pain).
The label supports the indication terms (neuropathic pain syndromes) but does not support the characterization 'commonly prescribed.'
Lyrica (pregabalin) is commonly prescribed for fibromyalgia.
The label supports the indication (fibromyalgia) but does not support the characterization 'commonly prescribed.'
Lyrica (pregabalin) is commonly prescribed for certain types of seizures.
The label supports the seizure indication but does not support the characterization 'commonly prescribed.'
Contradictions
Important Omissions
Boxed warnings (if any) were not evaluated because the provided label excerpts do not include a boxed warning section.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No claims in the response conflict with the provided label. Some mechanistic benzodiazepine-negation statements are unsupported rather than contradictory. Sedation/dizziness claims are consistent with label warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Benzodiazepine-related statements are not supported by the provided label excerpts.
Suggested Improvement
Remove or rephrase benzodiazepine-negation/comparison claims unless supported by label text; stick to label-supported indications (neuropathic pain syndromes, fibromyalgia, adjunctive partial-onset seizures) and label-described effects (dizziness/somnolence).